GETI.B

212

+0.14%↑

CAMX

687.5

-5.76%↓

BIOAB

267.6

-1.18%↓

VITR

134.5

-0.15%↓

EKTA.B

49.72

-0.32%↓

GETI.B

212

+0.14%↑

CAMX

687.5

-5.76%↓

BIOAB

267.6

-1.18%↓

VITR

134.5

-0.15%↓

EKTA.B

49.72

-0.32%↓

GETI.B

212

+0.14%↑

CAMX

687.5

-5.76%↓

BIOAB

267.6

-1.18%↓

VITR

134.5

-0.15%↓

EKTA.B

49.72

-0.32%↓

GETI.B

212

+0.14%↑

CAMX

687.5

-5.76%↓

BIOAB

267.6

-1.18%↓

VITR

134.5

-0.15%↓

EKTA.B

49.72

-0.32%↓

GETI.B

212

+0.14%↑

CAMX

687.5

-5.76%↓

BIOAB

267.6

-1.18%↓

VITR

134.5

-0.15%↓

EKTA.B

49.72

-0.32%↓

Search

Vivesto AB

Fermé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-1.2M

-9.5M

BPA

-0.018

Employés

4

Dividendes

By Dow Jones

Prochains Résultats

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

11M

141M

Ouverture précédente

0

Clôture précédente

0

Vivesto AB Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 sept. 2025, 22:41 UTC

Principaux Mouvements du Marché

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept. 2025, 16:04 UTC

Principaux Mouvements du Marché

Upexi Shares Climb on Solana Gains

14 sept. 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sept. 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sept. 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sept. 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 sept. 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14 sept. 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sept. 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14 sept. 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sept. 2025, 08:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

12 sept. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

12 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 20:09 UTC

Résultats

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept. 2025, 18:38 UTC

Market Talk
Résultats

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept. 2025, 16:22 UTC

Résultats

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 16:19 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 sept. 2025, 16:11 UTC

Résultats

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept. 2025, 15:07 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparaison

Variation de prix

Vivesto AB prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
help-icon Live chat